Editorial Policy

Every factual claim on this site is graded. Tier 1 — regulatory documents: the FDA prescribing information, approval records, and trial-registry entries. Tier 2 — peer-reviewed literature: journal publications of TAZPOWER, MMPOWER-3, PROGRESS-HF, ReCLAIM, and the ss-31 basic-science record. Tier 3 — public market data: pricing databases, manufacturer public disclosures, program documentation. Where claims of different tiers conflict, the higher tier wins and the conflict is noted.

Phrases like “research suggests,” “clinical trials investigate,” and “published data demonstrates” mark what the record actually supports. The site does not use treatment, cure, or efficacy language outside quoted regulatory or trial findings, and it does not publish dosing or usage guidance in any form.

Numbers are never free-floating: a list price carries its database and date, a safety frequency carries its label section, an endpoint result carries its trial and population. If a figure cannot be attributed to a Tier 1–3 source, it does not appear. Where a channel is empty — for example, the documented absence of a manufacturer coupon program — the page says so rather than inventing an answer.

Market content is industry research, never purchasing guidance: market pages name no sellers, link no storefronts, and describe channels structurally. Comparison pages (forzinity vs ss-31, forzinity vs 2S50) compare documented parameters without recommending any channel or product.

Pages carry a research-review date and are re-checked when the underlying documents move: label revisions, new trial publications, pricing changes, or program launches. Material corrections are made in place and acknowledged to the correspondent where one prompted them.

Errors of fact are fixed regardless of when found. If you spot one, use the contact page — include the page URL and the sourced correct figure, and the fix is usually published quickly.